Drug name - Dificid

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8586551 CUBIST PHARMS LLC 18-membered macrocycles and analogs thereof
Jul, 2023

(7 months from now)

US7378508 CUBIST PHARMS LLC Polymorphic crystalline forms of tiacumicin B
Jul, 2027

(4 years from now)

US7863249 CUBIST PHARMS LLC Macrolide polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof
Jul, 2027

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8586551

(Pediatric)

CUBIST PHARMS LLC 18-membered macrocycles and analogs thereof
Jan, 2024

(1 year, 1 month from now)

US7906489 CUBIST PHARMS LLC 18-membered macrocycles and analogs thereof
Mar, 2027

(4 years from now)

US8859510 CUBIST PHARMS LLC Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof
Jul, 2027

(4 years from now)

US7863249 CUBIST PHARMS LLC Macrolide polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof
Jul, 2027

(4 years from now)

US7906489

(Pediatric)

CUBIST PHARMS LLC 18-membered macrocycles and analogs thereof
Sep, 2027

(4 years from now)

US8859510

(Pediatric)

CUBIST PHARMS LLC Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof
Jan, 2028

(5 years from now)

US7378508

(Pediatric)

CUBIST PHARMS LLC Polymorphic crystalline forms of tiacumicin B
Jan, 2028

(5 years from now)

US7863249

(Pediatric)

CUBIST PHARMS LLC Macrolide polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof
Jan, 2028

(5 years from now)

US9808530 CUBIST PHARMS LLC Composition of tiacumicin compounds
May, 2034

(11 years from now)

US9808530

(Pediatric)

CUBIST PHARMS LLC Composition of tiacumicin compounds
Nov, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
New Patient Population (NPP) Jan 24, 2023
Orphan Drug Exclusivity (ODE) Jan 24, 2027
Pediatric Exclusivity (PED) Jul 24, 2023

Drugs and Companies using FIDAXOMICIN ingredient

Market Authorisation Date: 27 May, 2011

Treatment: Treatment of microbial infections; Treatment of clostridioides difficile-associated diarrhea (cdad) in patients from 6 months of age and older

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
200MG TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.